ESR1 and neoplasm: These models were adjusted for the baseline value of the outcome and tumor receptor status (triple negative; Her2Neu+, estrogen receptor (ER)+ or progesterone receptor (PR)+; Her2Neu+, ER– and PR–; Her2Neu–, ER+ or PR+ (for breast cancer patients)) as well as for the stratification factors: age (25–40, 40–65, and 65–75), adjuvant treatment (radiotherapy yes/no before chemotherapy), hospital, tumor site, and use of tissue expander (for breast cancer patients yes vs. no).